AndreiRShustovMD

Oncology • Seattle, WA

Assistant Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Are you Dr. Shustov?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 60 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
825 Eastlake Avenue E
G3200
Seattle, WA 98109
Phone+1 206-288-6739

Fax+1 206-288-6473
Is this information wrong?

Summary

Dr. Andrei Shustov, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington and Pennsylvania. He is affiliated with UW Medicine/University of Washington Medical Center and is an Assistant Professor at University of Washington School of Medicine.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
Wellspan Health/York HospitalResidency, Internal Medicine, 2000 - 2003
Crimea State Medical UniversityClass of 1993

Certifications & Licensure

WA State Medical License 2003 - 2026
PA State Medical License 2000 - 2003

Clinical Trials

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma Start of enrollment: 2009 Jul 01
Terminated
Phase 2
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma Start of enrollment: 2006 Sep 01
Completed
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma Start of enrollment: 2013 Jul 16
Active, not recruiting
Phase 2
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
Active, not recruiting
Phase 2
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Start of enrollment: 2018 Jan 03
Withdrawn
Phase 1, Phase 2
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma Start of enrollment: 2016 Oct 25
Terminated
Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA Start of enrollment: 2019 Apr 24
Completed
Phase 3
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Join now to see all

Publications & Presentations

PubMed

2 citations
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, Olga Sala-Torra, Philip A Stevenson, Christen H Martino, Yajuan J Liu, Min Fang, Mary-Elizabeth M Percival, An...> ;Leukemia & Lymphoma. 2023 May 1
14 citations
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Kerry J Savage, Steven M Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Ke...> ;Blood Advances. 2022 Oct 11
6 citations
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Kelsey-Leigh A Garcia, Sindhu Cherian, Philip A Stevenson, Christen H Martino, Andrei R Shustov, Pamela S Becker, Mary-Elizabeth M Percival, Vivian G Oehler, Anna B Ha...> ;Cancer. 2022 Apr 1
80 citations
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
S Horwitz, O A O'Connor, B Pro, L Trümper, S Iyer, R Advani, N L Bartlett, J H Christensen, F Morschhauser, E Domingo-Domenech, G Rossi, W S Kim, T Feldman, T Menne, D...> ;Annals of Oncology. 2022 Mar 1
32 citations
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a mu...
Christiane Querfeld, John A. Thompson, Matthew H. Taylor, Jennifer DeSimone, Jasmine Zain, Andrei R. Shustov, Carolyn Johns, Sue Ann McCann, Gloria H. Y. Lin, Penka S....> ;The Lancet. Haematology. 2021 Oct 7
25 citations
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single cen...
Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujj...> ;The Lancet. Haematology. 2021 Aug 1
38 citations
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Ranjana H Advani, Tetiana Skrypets, Monica Civallero, Michael A Spinner, Martina Manni, Won Seog Kim, Andrei R Shustov, Steven M Horwitz, Felicitas Hitz, Maria Elena C...> ;Blood. 2021 Jul 22
Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome
Jake C Robertson, Mustufa A. Jafry, Lori Soma, Andrei R. Shustov, Michi M. Shinohara> ;Cureus. 2021 Jun 6
Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project.
Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won-Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Ele...> ;Blood. 2021 Mar 30
21 citations
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.
Andrei R. Shustov, Maria Elena Cabrera, Monica Civallero, Monica Bellei, Young Hyeh Ko, Martina Manni, Tetiana Skrypets, Steven M. Horwitz, Carmino Antonio De Souza, J...> ;Blood Advances. 2021 Feb 9
76 citations
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K. Lue, Francesca Montanari, Enrica Marchi, Changchun Deng, Hye A. Kim, Aishling M. Rada, Alice T. Jacob, Cristina Kin...> ;Blood. 2020 Nov 10
30 citations
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.
Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahm...> ;Journal of the National Comprehensive Cancer Network. 2020 Nov 2
6 citations
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.
Frederick Lansigan, Steven M. Horwitz, Lauren C. Pinter-Brown, Kenneth R. Carson, Andrei R. Shustov, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Chris...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 May 11
18 citations
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.
Mary Elizabeth Percival, Ryan C. Lynch, Anna B. Halpern, Mazyar Shadman, Ryan D. Cassaday, Chaitra S. Ujjani, Andrei R. Shustov, Yolanda D. Tseng, Catherine Liu, Steve...> ;JCO Oncology Practice. 2020 May 5
55 citations
Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines
Neha Mehta-Shah, Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Dogan, Kristopher R. Fisher, Aaron M. G...> ;Journal of the National Comprehensive Cancer Network. 2020 May 1
4 citations
Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Ahmed Sawas, Helen Ma, Andrei R. Shustov, Pamela Hsu, Gajanan Bhat, Mark Acosta, Steven M. Horwitz, Owen A. O'Connor> ;Leukemia & Lymphoma. 2020 Apr 26
74 citations
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Christopher P. Fox, Monica Civallero, Young Hyeh Ko, Martina Manni, Tetiana Skrypets, Stefano Pileri, Seok Jin Kim, Maria Elena Cabrera, Andrei R. Shustov, Carlos S. C...> ;The Lancet. Haematology. 2020 Apr 1
59 citations
Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy
Stephen D. Smith, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian Wu, Jenna M. Voutsinas, Heather Rasmussen, Katherine Blue, Chaitra S. Ujjani, And...> ;British Journal of Haematology. 2020 Feb 6
5 citations
Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome.
Olivia R. Ware, Erica S. Tarabadkar, Andrei R. Shustov, Michi M. Shinohara> ;Journal of the American Academy of Dermatology. 2020 Feb 1
9 citations
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.
Anna B. Halpern, Nicholas P Howard, Megan Othus, Paul C. Hendrie, Nikita V Baclig, Sarah A. Buckley, Mary-Elizabeth M. Percival, Pamela S. Becker, Bart L. Scott, Vivia...> ;Leukemia. 2020 Feb 1
127 citations
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu, Francine M. Foss, Alison J. Moskowitz, Andrei R. Shustov, Satish Shanbhag, Lubomir Sokol, Steven P. Fling, Niras...> ;Journal of Clinical Oncology. 2020 Jan 1
20 citations
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Frederick Lansigan, Steven M. Horwitz, Lauren C. Pinter-Brown, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa...> ;Acta Haematologica. 2020 Jan 1
80 citations
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
Owen A. O'Connor, Lorenzo Falchi, Jennifer K. Lue, Enrica Marchi, Cristina Kinahan, Ahmed Sawas, Changchun Deng, Francesca Montanari, Jennifer E Amengual, Hye A. Kim, ...> ;Blood. 2019 Oct 24
64 citations
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids, Tapan M. Kadia, Andrei R. Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Za...> ;Blood. 2019 Oct 3
11 citations
How I treat primary cutaneous CD30+ lymphoproliferative disorders
Michi M. Shinohara, Andrei R. Shustov> ;Blood. 2019 Aug 8
Join now to see all

Authored Content

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

ALK-Negative Anaplastic Large Cell Lymphoma: Features and Outcomes of 235 Patients from the International T-cell ProjectJanuary 27th, 2021
Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care AwardNovember 25th, 2019
$Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma$
Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell LymphomaNovember 9th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

UW Medicine/University of Washington Medical CenterSeattle, Washington